In the present research article, nanosuspension of Meloxicam (BCS Class II) was prepared using Eudragit RS100 and stabilizer Poloxamber 407 with different ratios, a total of four formulations were prepared by using Quassi emulsification solvent diffusion technique ratio of drug: polymer: stabilizer with different ratio. Formulation F2 was found with particle size 80.00-100 nm and drug entrapment of 92.93 % with a zeta potential of -15. vitro drug release shows at 10 hrs. 96.44 %. Consider being optimized formulation with an increase in the dissolution of poorly water-soluble drugs being formulated in nanocomposite in the form of nanosuspension. By applying a statistical model for dissolution Higuchi model, Kerseymere pappa's model for optimizing F2 formulation shows the First order. Optimize F2 formulation with an increase in the dissolution/saturation solubility of 23.42±0.61 (μg /mL) of poorly water-soluble meloxicam belonging to BCS Class II (reported solubility with 3.5±0.50 μg /mL). The short-term stability study results revealed that the optimized F2 formulation stored at temperature 4oC shows no change in the in vitro drug release of the formulation compared to the release study tested after the formulation 0 time which means the nanosuspension is stable at the given temperature. Were as nanosuspension stored at a temperature of 37°C ± 2°C,65 % RH ± 5 % RH comparatively there is a change in the vitro drug release. So maximum stability obtained at the temperature 4oC Polymer Eudragit RS100 can be used for the preparation of nanosuspension with the help of Poloxamer 407 as a stabilizer.